Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Browsing: Uncategorized
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes
With a new year upon us, we are reminded of the year that is now coming to a close. 2011 has brought some amazing advancements in the healthcare and life science industry. OneMedForum SF 2012 is just around the corner and we are gearing up to present some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue, we bring four audio interviews with experts on new ideas and technologies making headway in 2012 and a reason why oral cancer mortality may decrease with a simple screening test. We hope…
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
Nearly 40 percent of oral cancer patients will die within five years of diagnosis.
Researchers discovered that miRNA plays an important role in a process known as transcription. .Since its miRNA is a mimic, it has the same sequence as the natural miRNA found in cells.
MRSA, which is commonly acquired through contact within the community, is resistant to most first-line antimicrobials on the market.